UBS Group’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$88 Sell
6,267
-300
-5% -$5 ﹤0.01% 10876
2026
Q2
$85 Buy
6,567
+2,381
+57% +$45 ﹤0.01% 10129
2026
Q1
$105 Sell
4,186
-2,000
-32% -$69 ﹤0.01% 10113
2025
Q4
$192 Sell
6,186
-17,228
-74% -$524 ﹤0.01% 10118
2025
Q3
$539 Buy
+23,414
New +$782 ﹤0.01% 9635
2025
Q1
– Sell
-1,633
Closed -$122 – 10655
2024
Q4
$122 Buy
+1,633
New +$98 ﹤0.01% 9630
2024
Q3
– Sell
-56
Closed -$3 – 9989
2024
Q2
$3 Buy
+56
New +$2 ﹤0.01% 9412
2024
Q1
– Sell
-29,080
Closed -$872 – 9925
2023
Q4
$872 Buy
+29,080
New +$1.75K ﹤0.01% 8489
2023
Q3
– Sell
-100
Closed -$10 – 9893
2023
Q2
$10 Buy
+100
New +$10 ﹤0.01% 8736
2022
Q4
– Sell
-5,606
Closed – – 11082
2022
Q3
$0 Buy
+5,606
New – ﹤0.01% 10840
2022
Q1
– Sell
-2,888
Closed -$5K – 10812
2021
Q4
$5K Sell
2,888
-202
-7% -$371 ﹤0.01% 9415
2021
Q3
$3K Buy
3,090
+939
+44% +$671 ﹤0.01% 8833
2021
Q2
$2K Sell
2,151
-1,378
-39% -$1K ﹤0.01% 8972
2021
Q1
$2K Buy
+3,529
New +$3.67K ﹤0.01% 8637

Other funds holding SABSW

UBS Group's SABSW Position: Q3 2026 in Review

UBS Group reduced its SAB Biotherapeutics Warrant (SABSW) stake by 4.6% in Q3 2026, selling an estimated $5 and leaving 6,267 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #10876.

UBS Group first reported a position in SABSW in Q1 2021 and has held it in 14 quarters since. The position peaked at $5K in Q4 2021. 10 funds tracked by Wall St. Rank hold SABSW as of Q3 2026.

  • UBS Group held 6,267 shares of SAB Biotherapeutics Warrant worth $88 as of Q3 2026.
  • UBS Group sold 300 SAB Biotherapeutics Warrant shares in Q3 2026, an estimated $5.
  • SAB Biotherapeutics Warrant made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10876 holding.
  • UBS Group first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and has held it in 14 quarters since.
  • UBS Group's SAB Biotherapeutics Warrant position peaked at $5K in Q4 2021.
  • 10 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.